New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 28, 2012
11:17 EDTNYMXNymox completes enrollment in U.S. Phase 3 NX02-0017 study of NX-1207
Nymox Pharmaceutical announced completion of patient enrollment in the company's pivotal U.S. Phase 3 NX02-0017 study of NX-1207 for BPH. This study is now closed to further enrollment. Top-line results from the large Phase 3 Study are expected in late 2013. Paul Averback MD, CEO of Nymox said, "Our drug development programs for NX-1207 include pivotal studies in the U.S. and Europe, re-injection studies in the U.S., prostate cancer trials, and other clinical and non-clinical research activities. Over 2000 patients have participated to date in NX-1207 trials. Final completion of enrollment in this major pivotal study is an important milestone in the NX-1207 development pathway. We look forward to further milestones as this and other trials are completed and results are reported."
News For NYMX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 14, 2014
10:05 EDTNYMXNymox reports Q3 EPS (2c) vs. (3c) last year
Reports Q3 revenue $81.1K vs. $88.9K.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use